On December 3rd, Merck announced that its new carbapenem/enzyme inhibitor complex, Imidacloprid for Injection, has been approved by the National Medical Products Administration for the treatment of the following infections caused by sensitive gram-negative bacteria in patients aged 18 and above: hospital acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VAP); Complex urinary tract infections (cUTIs) with limited or no alternative treatment options (including pyelonephritis); Complex intra-abdominal infections (cIAI) with limited or no alternative treatment options.
It is reported that bacterial resistance is a major challenge in the global public health field. According to data from the China Antibiotic Resistance Monitoring Network (CHINET), the incidence of CRE infections in China was 12.5% in 2014, 22.9% in 2016, and increased to 26.8% in 2019. Compared with 2015, the incidence of CRE in China has increased by over 58% in 2023.
Li Zhengqing, Senior Vice President of Merck Global and President of Merck China R&D Center, said, "The approval of Imidacloprid for Injection embodies Merck's deep accumulation in the field of antibiotics and continuous investment in innovative drug development pipelines, which will provide new choices for the clinical treatment of drug-resistant infections. Merck will persist in helping the development of China's medical and health industry, accelerating the introduction of more cutting-edge innovative drugs to Chinese patients, saving lives, and safeguarding health